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Abstract
Background: Adults with class II/III obesity [body mass index (in kg/m2) ≥35] may present with a
phenotype characterized by low lean mass and excess fat mass, a condition known as sarcopenic
obesity (SO). Little is known about the prevalence and relevance of SO in these individuals,
primarily due to a lack of relevant diagnostic criteria.
Objective: Here, we explored the definition of SO based on physical function as an outcome of
interest in adults with class II/III obesity and applied this definition to compare clinical
characteristics between SO and non-SO patients.
Methods: In this cross-sectional analysis, patients’ demographic, anthropometric, and biochemical
characteristics, as well as comorbidities and physical activity levels, were collected at an obesity
specialty clinic prior to any treatment. Body composition was assessed by dual-energy X-ray
absorptiometry. Physical function was assessed by self-reported difficulties with activities of daily
living (ADLs) from an 11-item questionnaire. Five SO definitions were tested against reported
difficulty with ADLs with the use of receiver operating characteristic (ROC) analysis.
Results: A total of 120 subjects (86% women) aged 46 ± 11 y were included. Based on ROC
analysis, SO was best defined by an appendicular skeletal mass (ASM)/weight x 100 (%) <19.35%
for women and <24.33% for men, resulting in a prevalence of 25% (n = 30, women 22.3%, men
41.2%). SO was significantly associated with older age, higher waist circumference, higher
triglycerides, greater use of antihypertensive medications, and lower physical activity.
Conclusions: In this sample of adults with class II/III obesity, difficulties with ADLs were best
associated with measures of ASM in relation to total body weight. Patients identified with SO
using this criterion presented with poorer clinical outcomes such as factors of elevated
cardiometabolic risk. Curr Dev Nutr 2018;2:nzx008.
Introduction
Low leanmass, also termed sarcopenia, is a condition primarily studied in the elderly as part of the
aging trajectory (1). Lower lean mass is associated with low physical activity, illness, inflamma-
tion, certain hormonal and neurologic conditions, and poorer quality of life, among other health
consequences (2). Increases in fat mass (FM) are typically seen frommiddle age up to age 60–70 y,
and are associated with a high prevalence of obesity among this age group.
In addition to aging-related changes in body composition, weight loss from obesity treatment
may result in reductions in both FM and lean mass. Weight cycling (weight gain after weight
loss) is common (3–5) and is associated with increased FM with lean mass remaining lower than
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baseline (i.e., prior to weight loss) (6). Repeated weight loss attempts,
combined with the normal aging trajectory, can put individuals at risk
for sarcopenia over time (5).
Sarcopenic obesity (SO) is described as the coexistence of low lean
mass with excess FM (7). Several definitions for sarcopenia exist, mostly
based on sex-specific cutpoints for lowmuscle mass derived either from
a young reference population or from a study cohort (8). Definitions
based on a health outcome of interest are highly relevant and have been
increasingly used (9–11). Due to the variety of definitions (for sarcope-
nia and obesity) andmethods to assess body composition, the estimates
of the prevalence of SO are highly variable (12). Studies have identified
SO in older adults (≥65 y of age) and those with certain health con-
ditions (11, 13, 14). In older adults, sarcopenia is associated with dif-
ficulties with activities of daily living (ADLs) (15, 16) and functional
impairment (17, 18). Excess FM and low lean mass can compound neg-
ative effects on cardiovascular and metabolic health (19–23), impacting
disability and mortality (24, 25). Although most studies to date have fo-
cused on older adults (≥60 y of age), recent data suggest younger and
middle-aged individuals may also present with SO (26, 27). Nonethe-
less, the lack of diagnostic criteria for sarcopenia in younger individu-
als, especially those with class II/III obesity [BMI (in kg/m2) ≥35], has
limited our understanding of the prevalence and clinical characteristics
of this condition in these individuals. Therefore, the primary purpose
of this study was to explore the definition of sarcopenia that best dis-
criminated adults with class II/III obesity based on a clinical outcome
of interest (data-driven approach), namely physical function. The sec-
ond was to apply this definition and compare the clinical characteristics
of subjects with and without SO.
Methods
Subjects
A cross-sectional analysis was conducted on patients from a multidis-
ciplinary obesity specialty clinic in Northern Alberta, Canada (popula-
tion 1.2million) (28). Patient history and clinical assessment were com-
pleted at the initial visit (i.e., prior to any weight loss treatment). Height
(centimeters), weight (kilograms), waist circumference (centimeters),
and blood pressure (expressed in mm Hg) were measured using stan-
dardized procedures, and BMI calculated as weight over height squared
(kg/m2), and categorized according to WHO criteria (29). Availability
of dual-energy X-ray absorptiometry (DXA) scans and further details
on data collection have been previously described (8). All subjects were
adults (18–69 y of age) with class II/III obesity who completed the ini-
tial assessment and had a DXA body composition scan in their medical
record (available from consecutive patients seen from January 2009 to
June 2012). Exclusion criteria included age (≥70 y), and those who had
incompleteDXAdata. Ethics approval was obtained from theUniversity
of Alberta Research Ethics Board.
Body Composition
DXA scans were conducted using Hologic Discovery A/W (Hologic
Inc., Bedford, MA) at a local imaging center, based on which FM,
lean mass [better termed lean soft tissue (LST)], fat-free mass (FFM;
composed of LST and bone) for the whole body, and segmental values
[appendicular skeletal mass (ASM); composed of the LST from the
arms and legs] were computed. These measures were adjusted by height
in square meters to calculate the FM index and ASM index (30).
Biochemical Analysis and Comorbidities
Biochemical data was collected from medical records and included in-
flammatorymarkers, lipid panel, glucose-relatedmeasurements, kidney
function, albumin, and vitamin D concentrations. Subjects with abnor-
mal biochemical values meeting criteria for either diabetes or predia-
betes were combined as a dichotomous variable.
Comorbid conditions were identified based upon review of medical
history and prescription medications and clinical and laboratory values
collected at the initial assessment. Metabolic syndrome was defined
using the National Cholesterol Education Program Adult Treatment
Panel III reference values; ≥3 out of 5 criteria being met indicated its
presence (31).
As was done previously (32–34), a multimorbidity categorical score
(0, 1, 2, ≥3) was used including 8 comorbidities: diabetes or predia-
betes, hypertension, dyslipidemia, metabolic syndrome, mental health,
chronic kidney disease, sleep apnea, and osteoarthritis.
Activity Level and Difficulties with Activities of Daily Living
Physical activity levelswere categorized as either “met” or “did notmeet”
Canadian Physical Activity Guidelines for Adults, defined as accumu-
lating ≥150 min of moderate-to-vigorous intensity activities in a week,
in bouts of ≥10 min (35).
An occupational therapy referral screening questionnaire based on
the Canadian Model of Occupational Performance (36) was used (see
Supplemental Table 1). This self-administered questionnaire included
11 items that asked about subjects’ experiences with managing ADLs
and the ability to perform a variety of tasks including: transferring in
and out of the car, bed, bathtub, or on and off the toilet; bathing; skin
care; personal hygiene; household tasks; and leisure activities. Other
items asked about home accessibility, falls or balance concerns, the im-
pact of excess skin on completing daily activities, the impact of fatigue
on completing daily activities, and whether a client uses or has consid-
ered custom footwear or orthotics. Options included “yes” or “no” an-
swers to each item, scored as 1 or 0, respectively. Subjects also had the
choice to report, “I have help” for some items, in which case a score of
1 was assigned. A higher overall score represented more items report-
ing difficulty with ADLs. A composite score for items on the question-
naire was calculated as a continuous variable (range 0–11). Additionally,
a dichotomous variable defined as “0–2” or “≥3” items was created to
explore the selected definition for SO, as described next.
SO Definition
Although all subjects had obesity (BMI≥35), the variability of percent-
age of FM was explored to avoid misclassification. As reported previ-
ously (and in the hereby shown results), percentage of FM fell within
several accepted criteria to define excess FM (8) for all patients. Based
upon this previous study (8), 5 previously published DXA-derived def-
initions of sarcopenia were explored (8, 21, 37–39; see Table 1). Be-
cause these definitions were not tested in regards to predictive ability,
the current study identified sarcopenia based on a clinically meaning-
ful cutpoint (data-driven approach) whereby a value was specified be-
low which individuals would be at increased risk for a health outcome
(9–11, 40, 41).
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TABLE 1 Bivariate correlations (Pearson’s r, P < 0.05) for the number of items (0–11) for self-reported difficulty with activities of
daily living with continuous body composition variables for the definitions of sarcopenia applied to the study sample1
Correlations with ADL difficulties, r (P value)
Definitions Reference All2 (n = 111)
Women
(n = 94) Men3 (n = 17)
ASM/weight x 100, % Levine and Crimmins, 2012 (21) –0.262 (0.005) –0.232 (0.024) –0.510 (0.037)
ASM/BMI, kg/m2 Batsis et al., 2015 (37) –0.187 (0.049) –0.158 (0.127) –0.526 (0.021)
ASM adjusted for height and FM Newman et al., 2003 (38) 0.108 (0.268) 0.195 (0.060) –0.177 (0.496)
(residuals) Johnson Stoklossa et al., 2017 (8) –0.084 (0.380) –0.150 (0.148) 0.239 (0.356)
FM:FFM ratio, centile Siervo et al., 2015 (39) 0.230 (0.015) 0.231 (0.025) 0.453 (0.068)
1Based on definitions identified/discussed in Johnson Stoklossa et al. (8). ADL, activity of daily living; ASM, appendicular skeletal mass; FMM, fat-free mass: FM, fat mass.
2Self-reported difficulty with ADLs available for n = 111.
3Spearman’s r reported for men due to small sample size (n < 30).
The choice of difficulty with ADLs as the outcome of interest
was due to the association with reduced physical function, increased
disability, and poor quality of life (15, 24, 40, 42). ADL difficulties are
notably a common health consequence of sarcopenia (43). Therefore,
our sex-specific cutpoints were developed based on its discriminative
and predictive ability, similar to previous studies in health and clinical
conditions (18, 24, 26, 41).
Correlation of the continuous body composition variable and the
continuous variable for difficultywithADLswas evaluated for each defi-
nition (Table 1), the definition of choice being the onemost significantly
correlated with difficulty with ADLs. Receiver operating characteristic
(ROC) curves were used to determine sex-specific cutpoints of the con-
tinuous body composition variable selected to define sarcopenia based
upon the 2 categories for difficulty with ADLs (0–2 items compared to
≥3 items), with high sensitivity as the priority criteria. The AUC was
then explored to identify optimal sex-specific cutpoints for the total dif-
ficulties with ADL score (continuous variable). These were used to cre-
ate a dichotomous variable: SO compared to non-SO based on impaired
and non-impaired ADLs, respectively. The body composition variable
calculated with the new cohort-derived cutpoints was then compared,
using chi-square test and kappa statistics, with the variable calculated
using the original study cutpoints from the selected SO definition, to
determine the level of agreement between the 2 definitions.
Statistical Analysis
Descriptive statistics were used as appropriate. Normality testing was
completed with the Shapiro–Wilk test. Mean values of 2 groups were
compared using independent samples t tests (Mann–Whitney U for
nonparametric data). Chi-square or Fisher’s exact test were used as ap-
propriate. Pearson’s or Spearman’s correlations were used to test the cor-
relation between 2 continuous variables for normally and non-normally
distributed variables, respectively. Cronbach’s alpha was used to deter-
mine the internal consistency of the items on the questionnaire for dif-
ficulty with ADLs. A P value of <0.05, based on 2-tailed tests, was con-
sidered statistically significant. Data analysis was completed with IBM
SPSS Statistics v23 (IBM Corp., Armonk, NY).
Results
Subject Characteristics
Of 167 cases reviewed, 120 had available DXA data. Subject demo-
graphics and anthropometrics are presented inTable 2. The sample was
predominately female, middle-aged,married or common law, educated,
and working outside the home. In terms of body composition, women
had lower LST and higher FM than did men, with similar findings be-
tween derivatives of these variables. Results for biochemical analysis
(serum, fasting) are presented in Supplemental Table 2. Five subjects
(4.3%) had renal impairment [estimated glomular filtration rate (eGFR)
<60 mL ·min−1 · 1.73 m−2]. All subjects presented with≥1 comorbid-
ity in addition to obesity (see Supplemental Table 3 for subjects’ clinical
characteristics). The most prevalent comorbidities were dyslipidemia,
followed bymetabolic syndrome and hypertension.Multimorbidity was
highly prevalent with 80.8% of patients having≥3 comorbid conditions
in addition to class II/III obesity. No differences were observed by sex
(P = 0.695) or BMI category (P = 0.427) between those meeting or not
meeting physical activity guidelines.
Of the 111 respondents (n = 9 with missing data), 11% reported no
difficulties with ADLs with no sex differences noted. Subjects across all
ages and BMI categories reported difficulties with ADLs, and>50% re-
ported difficultywith≥3 items. Prevalence of comorbidities was not dif-
ferent comparing subjects reporting difficulty with 0–2 items compared
to those reporting ≥3 items.
SO Definition
From the 5 sarcopenia definitions explored (Table 1), 2 were signif-
icantly correlated with items of difficulty with ADLs: ASM/weight x
100 (%) (21, 22) (r = –0.262, P = 0.005) and FM:FFM ratio (39)
(r = 0.230, P = 0.015). For both definitions, lower lean mass was asso-
ciated with a higher number of items of difficulty with ADLs. Nonethe-
less, only ASM/weight x 100 (%) was significantly correlated for both
sexes [women (r = –0.232, P = 0.024); men (rs = –0.510, P = 0.037)].
Therefore, this variable was selected to define sarcopenia in our cohort.
ASM/weight x 100 (%) for the entire cohort (n = 120) was
21.7%± 2.6%; median and range: 21.5% (16.2–29.2%). Cohort-derived
sex-specific cutpoints were then determined; for women the value was
19.4% (sensitivity 86%, specificity 29%) and it was 24.3% (90% sensitiv-
ity, 86% specificity) for men. Differences were not driven solely by men,
as the best agreement was achieved with the sex-specific cutpoint ap-
plied to the entire data-set (data not shown). Applying these cutpoints,
the prevalence of SO in the entire sample was 25% (22.3% women;
41.2%men).Mean values for ASM/weight x 100 (%)were 19.3%± 1.8%
for subjects with SO and 22.5% ± 2.3% for the group with non-SO
(P < 0.0001).
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TABLE 2 Demographic, anthropometric, and body
composition characteristics of adults with class II/III obesity
(n = 120)1
Variables
% or mean ± SD; median
(range)
Demographics
Sex
Female 85.8
Age, y 46.9 ± 11.1; 49.0 (23–69)
Marital status
Single 23.3
Married/common law 67.5
Divorced/separated/widowed 9.2
Education
Some high school 2.5
Completed high school 97.5
Completed postsecondary 53.3
Employment
Full-time 53.3
Part-time 14.2
Unemployed 6.7
On disability 7.5
Homemaker 5.8
Retired 12.5
Smoking
Never 45.5
Former 47.3
Current 7.3
Age of obesity onset
Pediatric, ≤19 y 46.7
Adult, ≥20 y 53.3
Anthropometrics
Height, cm 166.0 ± 7.64; 165.0
(148.6–187.1)
Weight,2 kg 120.2 ± 19.6; 116.2 (88.9–180.7)
BMI,2 kg/m2 43.5 ± 5.7; 42.3(34.9–58.5)
35.0–39.9 33.3
40.0–44.9 32.5
45.0–49.0 19.2
≥50.0 15.0
Waist circumference, cm3 123.3 ± 13.2; 122.5 (93.5–163.0)
Body composition4
ASM, kg F: 24.7 ± 3.7; 24.2 (17.4–35.4)2
M: 34.2 ± 5.2; 35.3 (27.0–44.9)
ASMI, kg/m2 F: 9.2 ± 1.2; 9.1 (6.7–12.8)
M: 10.9 ± 1.3; 10.9 (8.7–13.6)
ASM/weight x 100, % F: 21.2 ± 2.1; 21.0 (16.2–28.3)
M: 24.9 ± 2.8; 24.9 (20.2–29.2)
FM, % F: 48.0 ± 4.2; 48.3 (32.3–57.4)
M: 41.4 ± 5.6; 39.7 (31.9–53.2)
FMI, kg/m2 F: 20.6 ± 3.8; 20.0 (13.9–30.9)2
M: 18.0 ± 3.7; 16.9 (13.4–24.9)
1ASM, appendicular skeletal mass; ASMI, ASM index; FM, fat mass; FMI, fat mass
index.
2Variable not normally distributed for women.
3Waist circumference available for 78% (n = 94).
4All body composition variables were statistically different between sexes.
Correlations for SO definition (as dichotomous variable: SO com-
pared to non-SO) with difficulty with ADLs (0–2 compared to ≥3
items) were significant (P= 0.006). The ability for these ADL categories
to discriminate sarcopenia was moderate for women (AUC = 0.60;
95% CI: 0.49, 0.71) and strong for men (AUC = 0.90; 95% CI: 0.74,
1.00). There was a high level of agreement (k = 0.915) between our
cohort-specific definition and Levine and Crimmins’ (21) published
cutpoints for ASM/weight x 100 (%) derived from a young reference
group.
The ADL questionnaire had good internal consistency (11 items,
α = 0.848). As such, nearly three-quarters of subjects with SO reported
difficulty with ≥3 items compared to less than half (44%) of non-SO
subjects. Values for ASM/weight x 100 (%) were lower for subjects who
responded “yes” to 5 separate ADL items: transfers (P = 0.046), wip-
ing self (P = 0.030), fatigue as a barrier to household tasks (P = 0.017)
and leisure activities (P = 0.009), and access to household rooms
(P = 0.020). Overall prevalence of difficulty with ADLs by SO status is
presented in Figure 1, with differences identified for 6 of the 11 items:
transfers (P = 0.023), falls (P = 0.030), dress self (P = 0.021), fatigue
as a barrier to household (P = 0.048) and leisure activities (P = 0.004),
and excess skin (P = 0.025).
Clinical Characteristics of SO
No differences for most demographic variables were observed by sar-
copenia status, except for age and sex (prevalence by sex as already re-
ported). Age range was 23–69 and 24–68 y for SO compared to non-SO
groups, respectively. Mean age was higher for the SO group (50.7± 12.7
compared to 45.7 ± 10.3 y, P = 0.033). Prevalence of SO was signifi-
cantly higher among subjects aged ≥ 65 y (66.7% compared to 22.8%,
P = 0.016). Smoking status (never compared to former) was not differ-
ent between groups and no current smokers were identified with SO.
Although all waist circumference measurements exceeded recommen-
dations, individuals with SO presented with a higher mean waist cir-
cumference compared to their counterparts (130.2 ± 21.1 compared to
121.1 ± 11.7 cm, P = 0.004).
A comparison of clinical variables (metabolic and functional) by sar-
copenia status is presented in Table 3. No differences between groups
were identified for most biochemical variables, except for albumin and
triglycerides. Only 2 subjects had hypoalbuminemia and both had sar-
copenia. SO was associated with higher triglyceride concentrations
(2.06 ± 1.00 compared to 1.62 ± 0.73 mmol/L, P = 0.040), which in
turn overall exceeded the normal reference value (<1.7 mmol/L). Only
a trend towards a difference was found between groups comparing ab-
normal to normal triglyceride concentrations (see Table 3).
SO was associated with a greater prevalence of renal impairment
(eGFR <60 mL · min−1 · 1.73 m−2), yet overall the majority of the co-
hort had normal renal function. There were no differences for mean
C-reactive protein (CRP) concentrations (SO, 8.07 ± 5.40 compared to
7.58 ± 6.51 mg/L for non-SO, P = 0.731). Presence of comorbid con-
ditions was not different between groups. Use of medications for hy-
pertension was higher among SO patients, although no difference was
identified for the prevalence of hypertension or blood pressure mea-
sures among groups (data not shown).
Individuals with SO were less likely to meet physical activity guide-
lines (see Table 3). For subjects who met the guidelines, 95.8% were in
the non-SO group.
Discussion
This is the first study to define SO in an adult cohort with class II/III
obesity using a clinically relevant outcome of interest, ADL difficulty.
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FIGURE 1 Comparison of items for self-reported difficulty with activities of daily living with body composition phenotype groups:
sarcopenic obese (n = 27, left bar) compared to nonsarcopenic obese (n = 84, right bar). The occupational therapy screening
questionnaire was completed by each subject at the initial clinic assessment with 11 items that asked about their experiences and ability to
perform a variety of activities of daily living tasks. *Results for items that were significantly different between the groups, P < 0.05.
Maintaining ADL functioning is essential for independence and opti-
mal quality of life (44, 45). In our definition (ASM/weight x 100, %),
reduced ADLs in an adult cohort with class II/III obesity were predicted
by the amount of body weight (load) in proportion to their lean mass
(capacity—load bearing) (12). In other words, this concept accounts for
the magnitude of body weight in relation to lean mass that would lead
to functional impairments. This concept is in accordance with other
studies that reported an association between lower relative lean mass
and greater difficulty with ADLs and function (18, 21, 46). We propose
that the relation between body composition and physical function may
provide a useful marker for the clinical diagnosis of SO in adults with
class II/III obesity defined as measure of ASM in relation to total body
weight. Using this definition, we reported that, although present across
the age spectrum, SO was associated with older age, higher waist cir-
cumference, higher triglycerides, use of anti-hypertensive medications,
and inactivity.
Defining SO is challenging (12). As explored in our previous pub-
lication (8), definitions accounting for measures of body mass or FM
may better identify these individuals. Here, lower ASM/weight x 100
(%) was correlated with a higher number of items for difficulty with
ADLs. Per our previous study (8), Levine and Crimmins’ (21) cutpoints
identified 23.2% women and 58.5% men with SO in the present co-
hort. Due to the uniqueness of our cohort (non-elderly adults with class
II/III obesity) and the interest to tie the definition to a clinical outcome,
cohort-and sex-specific cutpoints were explored using the same body
composition variable (ASM/weight x 100, %). The resulting cutpoints
(women <19.35%, men <24.33%) were very similar for women and
slightly lower for men, compared to the Levine and Crimmins (21) val-
ues, leading to an overall higher prevalence of SO (25% compared to
10% for the former study; sex-specific prevalence not reported).
SO was identified in more men than women (41.2% compared to
22.3%). Sex differences in the prevalence of SO are variable, with some
studies reporting a higher prevalence for women (38, 46), others for
men (15, 26, 47), or mixed results depending on the definition applied
(37, 48). Interestingly, we showed a consistently higher prevalence in
men, among 18 definitions (8). Differences in body composition be-
tween the sexes may be associated with sex hormones including estro-
gen and testosterone, influencing both fat and lean tissues (49–52).
There were not as many differences as expected when comparing
biochemical variables between sarcopenic and nonsarcopenic obese
groups. Although hypoalbuminemia was correlated with SO, our n = 2
precludes any meaningful conclusion. Elevated CRP, a biomarker
for systemic inflammation and associated with obesity, sarcopenia,
metabolic syndrome, and cardiovascular disease, was identified in
∼30% of the study cohort, but the prevalence was not different between
groups. Our results are in agreement with those of Levine and Crim-
mins (21), who found no difference in CRP values between both sets
of subjects in their obese groups (sarcopenic and nonsarcopenic). Al-
though studies of older adults report an association between SO with
metabolic syndrome and insulin resistance (21, 22), we were unable to
observe such differences. Unfortunately, fasting insulin was not avail-
able for our cohort.
Although the prevalence of metabolic syndrome was similar be-
tween groups, a greater prevalence of reporting 2 of the 5 criteria
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TABLE 3 Comparison of clinical variables between sarcopenic obese versus nonsarcopenic obese groups (n = 120)1
Variables2 All3 (n)
Sarcopenic obese4
(n = 30)
Nonsarcopenic
obese4 (n = 90) P value
Biochemical, %
Fasting glucose > 6.0 mmol/L 114 30.8 31.8 0.511
HbA1C > 6.5 115 18.5 28.4 0.306
eGFR < 60 mL · min−1 · 1.73 m−2 116 10.7 2.3 0.055
TChol > 6.2 mmol/L 115 11.1 9.1 0.755
LDL > 3.2 mmol/L 115 29.6 38.6 0.495
HDL: F < 1.3, M < 1.0 mmol/L 115 55.6 63.6 0.450
TG > 1.7 mmol/L 115 59.3 38.6 0.059
CRP > 10.0 mg/L 112 28.0 28.7 0.943
Albumin < 35 g/L 114 100 0.0 0.009
25-OH vitamin D3 <80 nmol/L 113 61.5 65.5 0.710
Comorbidities, %
Abnormal glycemic control 114 34.6 43.2 0.436
On medication 120 13.3 18.9 0.588
Hypertension 115 71.4 69.0 0.805
On medication 120 50.0 28.9 0.035
Dyslipidemia 115 96.4 90.9 0.342
On medication 120 26.7 15.6 0.173
Mental health 120 56.7 55.6 0.915
On medication 120 36.7 27.8 0.358
Metabolic syndrome 117 72.4 69.3 0.819
Osteoarthritis 120 40.0 23.3 0.077
Sleep apnea 120 43.3 34.4 0.382
Multimorbidity score, % 120
≥3 80.0 81.1 0.885
Activity level, % 120 0.007
Meets guidelines 3.3 25.6
Difficulty with ADLs, % 111
Any item 85.2 78.6 0.584
Less vs. more items 0.008
0–2 items 25.9 56.0
≥3 items 74.1 44.0
1ADL, activity of daily living; CRP, C-reactive protein; eGFR, estimated glomular filtration rate; HbA1C, glycated hemoglobin; TChol, total cholesterol; TG, triglyceride.
2Variables were compared by category: biochemical (abnormal vs. normal); comorbidities (present vs. absent); multimorbidity score (<3 vs. ≥3); difficulty with ADLs: any
item (yes vs. no).
3All: total number of participants with data for each variable from the entire cohort.
4Percentages reported as a total within each body composition group.
for metabolic syndrome (high triglycerides and high waist circumfer-
ence) was reported among the SO group. The hypertriglyceridemic
waist phenotype has been used to identify those with increased visceral
adiposity, which in turn is associated with increased cardiometabolic
risk and mortality (53, 54). In addition to cardiometabolic risk, the
difference in serum triglyceride concentrations between subjects with
SO and those without may serve as a biomarker for other abnormali-
ties.
Regarding physical activity, 80% of subjects did not meet activity
guidelines, which is similar to nationally reported levels (78%) (55). No
difference by sex or BMI categories between those who met or did not
meet the guidelines was observed, but a greater proportion of individ-
uals with SO did not meet the activity guidelines. It is possible that a
proportion of SO patients were unable to perform physical activity, and
hence did not meet the guidelines.
Our study has several limitations including the tool to assess ADLs.
Although each item addressed a category of ADL difficulty, such as
transfers, the question as stated often included >1 option (i.e., car,
bed, bathtub, and toilet). It was not possible to evaluate, for exam-
ple, if patients only had difficulty with transferring in and out of their
car or if they experienced difficulty with transfers for all the examples
provided. Additionally, reasons for the difficulties or the level of diffi-
culty experienced cannot be ascertained. Nonetheless, this tool was able
to differentiate patients by sarcopenia status, highlighting the potential
use of this or similar tools in research and clinical settings. Unfortu-
nately, measures of muscle strength, quality, or function were not avail-
able. Further assessment of factors influencing difficulty in participation
and performance of ADLs, including physical function, cognition, and
strength, is needed (45). Additional limitations of our study include a
small sample size of a convenience sample, and the cross-sectional de-
sign. Our data-driven approach to define this abnormal body composi-
tion type should not be seen as a limitation, as similar approaches have
been previously used (18, 24, 26, 41, 56). Nonetheless, the definition
hereby used requires external validation in different patient cohorts.
Our study used state-of-the-art body composition data (DXA) con-
tributing to the limited research on subjects with BMI >40 who may
be excluded from studies due to equipment weight capacity limits (57).
Additionally, this study highlights the impact of SO in younger and
middle-aged adults, who, contrary to expectations, may also experience
SO and its clinical consequences. Further research is needed to validate
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cutpoints for SO in relation to clinical outcomes, such as the items of
self-reported difficulty with ADLs, for adults with class II/III obesity.
Unfortunately, wewere unable to evaluatewhether the performance and
discriminative capacity of SO are body size dependent—i.e., valid for
those with obesity class I. Likewise, our definition of SO does not ac-
count for age (although <6% of participants were ≥65 y old), which is
an important determinant of difficulties with ADLs and would proba-
bly lead to lower cutpoints for younger individuals. Notably, age was not
different by sarcopenia status.
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